z-logo
open-access-imgOpen Access
Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
Author(s) -
NingYi Hsia,
ChunJu Lin,
ChunTing Lai,
Henry Bair,
Cheng-Hsien Chang,
JaneMing Lin,
YiYu Tsai
Publication year - 2021
Publication title -
case reports in ophthalmological medicine
Language(s) - English
Resource type - Journals
eISSN - 2090-6722
pISSN - 2090-6730
DOI - 10.1155/2021/8887362
Subject(s) - aflibercept , medicine , ophthalmology , macular edema , ranibizumab , retinal , neovascularization , choroidal neovascularization , triamcinolone acetonide , surgery , bevacizumab , chemotherapy , angiogenesis
We report the rescue effect of intravitreal aflibercept injections on retinal neovascularization and macular edema due to Eales disease. Case 1 was a 36-year-old female. Intravitreal aflibercept was administered as rescue therapy after persistent retinal neovascularization following retinal photocoagulation, periocular triamcinolone, and intravitreal ranibizumab injection. Retinal neovascularization initially regressed, but recurred after 5 months along with macular edema. Two more intravitreal aflibercept injections were given, and retinal neovascularization with macular edema regressed. Her vision improved to 20/25 and remained stable after 43 months. Case 2 was a 27-year-old female. Intravitreal aflibercept was administered after persistent retinal neovascularization and macular edema following periocular triamcinolone injection. The macular edema initially subsided but recurred after 3 months. Intravitreal aflibercept injections were then administered once every three months to maintain her vision 20/20. The patient has been followed up for 28 months. Intravitreal aflibercept was effective as a rescue therapy in the treatment of Eales disease to regress retinal neovascularization, though repeated injections were necessary in cases of recurrence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom